CXCR4 and B-cell non-Hodgkin lymphoma: Three articles described the application of immuno-PET in CD20+ B-cell lymphomas [13,14,15], while the fourth article dealt with CD184 (better known as CXCR4, chemokine receptor type 4, or fusin) targeting with [68Ga]pentixafor in patients with non-Hodgkin’s lymphoma (NHL) [16].